Please assess the completion status of the following clinical trial:

Trial Title: Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes duration between 2 and 20 years~* Two or more components of metabolic syndrome:~  * HDL-cholesterol \< 1.0 mmol/L (in males) or \< 1.3 mmol/L (in females)~ * Elevated triglycerides (\> 1.7 mmol/L)~ * Elevated blood pressure (\> 130 mmHg systolic and/or \>85 mmHg diastolic or antihypertensive treatment)~ * Elevated waist circumference (\> 102 cm in males, \> 85 cm in females)~* Or at least one of the following~  * Carotid ultrasound showing an IMT \> 1 mm and plaque of carotid artery or~ * Left ventricular hypertrophy or~ * Increased UACR in the absence of other renal diseases than diabetic nephropathy~* Increased hsCRP (\> 2 mg/l but \< 10 mg/l) at or within 6 months prior to screening and/or increased PAI 1 (\> 15 ng/ml) at or within 6 months prior to screening (the historical hsCRP or PAI 1 value can be used only if the patient was in stable conditions regarding the concomitant diseases and statin therapy since the time point of measurement)~* Stable treatment with statins (if tolerated/clinically indicated)~* Age 40 - 75 years~Exclusion Criteria:~* Major cardiovascular (CV) event with need for oral anticoagulation or platelet inhibitor therapy or acute coronary syndrome \< 12 month before study entry~* Sustained uncontrolled hypertension: systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 100 mmHg~* Hypersensitivity to the active substance or to any of the excipients~* Active clinically significant bleeding~* Lesion or condition, if considered to be a significant risk for major bleeding~* Concomitant treatment of acute coronary syndrome (ACS) with antiplatelet therapy in patients with a prior stroke or a transient ischemic attack (TIA)~* Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C~* Chronic renal failure with eGFR \< 15 ml/min (MDRD formula)~* Pregnant or breast-feeding woman and woman without adequate method of contraception.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): 5mg b.i.d. for 20 weeks (primary phase) + additional 32 weeks (extension phase)
- Aspirin (Type: ACTIVE_COMPARATOR): 100mg once daily for 20 weeks (primary phase) + additional 32 weeks (extension phase)

Based on this trial design, predict the completion outcome and termination type (if applicable).